JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB4070

Anti-E2F1 antibody [KH95]

1

(1 Review)

|

(21 Publications)

Knockout Tested Mouse Monoclonal E2F1 antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 21 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human E2F1.

View Alternative Names

RBBP3, E2F1, Transcription factor E2F1, E2F-1, PBR3, Retinoblastoma-associated protein 1, Retinoblastoma-binding protein 3, pRB-binding protein E2F-1, RBAP-1, RBBP-3

6 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-E2F1 antibody [KH95] (AB4070)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-E2F1 antibody [KH95] (AB4070)

ab4070 staining human tonsil by IHC-P.

Western blot - Anti-E2F1 antibody [KH95] (AB4070)
  • WB

Lab

Western blot - Anti-E2F1 antibody [KH95] (AB4070)

Western blot : Anti-E2F1 antibody [KH95] (ab4070) staining at 1/500 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in magenta. In Western blot, ab4070 was shown to bind specifically to E2F1. A band was observed at 47 kDa in wild-type HCT 116 cell lysates with no signal observed at this size in E2F1 knockout cell line. To generate this image, wild-type and E2F1 knockout HCT 116 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-E2F1 antibody [KH95] (ab4070) at 1/500 dilution

Lane 1:

Wild-type HCT 116 cell lysate at 20 µg

Lane 2:

E2F1 knockout HCT 116 cell lysate at 20 µg

Lane 3:

Wild-type HEK-293 ab259780 cell lysate at 20 µg

Lane 4:

E2F1 knockout HEK-293 <a href='/en-us/products/cell-lines/human-e2f1-knockout-hek-293-cell-line-ab269502'>ab269502</a> cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution

false

Western blot - Anti-E2F1 antibody [KH95] (AB4070)
  • WB

Lab

Western blot - Anti-E2F1 antibody [KH95] (AB4070)

Lanes 1 - 5 : Merged signal (red and green). Green - ab4070 observed at 55 kDa. Red - loading control ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) observed at 37 kDa.

ab4070 was shown to react with E2F1 in wild-type HEK-293 cells in Western blot with loss of signal observed in E2F1 knockout sample. Wild-type HEK-293 and E2F1 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab4070 and ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) overnight at 4°C at a 1 in 500 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-E2F1 antibody [KH95] (ab4070) at 1/500 dilution

Lane 1:

Wild-type HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate at 20 µg

Lane 2:

E2F1 knockout HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate at 20 µg

Lane 2:

Western blot - Human E2F1 knockout HEK-293 cell line (<a href='/en-us/products/cell-lines/human-e2f1-knockout-hek-293-cell-line-ab269502'>ab269502</a>)

Lane 3:

Hep G2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 20 µg

Lane 4:

U-2 OS (Human bone osteosarcoma epithelial cell line) whole cell lysate at 20 µg

Lane 5:

HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 20 µg

Predicted band size: 47 kDa

Observed band size: 55 kDa

false

Western blot - Anti-E2F1 antibody [KH95] (AB4070)
  • WB

CiteAb

Western blot - Anti-E2F1 antibody [KH95] (AB4070)

Western Blotting using Anti-E2F1 antibody [KH95]Anti-E2F1 antibody [KH95], ab4070. Publication image from Meng, X. et al., 2020, Nat Commun, 32001707. Legend direct from paper.

BIP-MPC-NP restrains E2F1-mediated DNA damage repair modules via the inhibitory effect of TTP.a E2F1 binding sites within a region spanning ± 3 kb around TSS in the whole genome. b The signal peaks located in the promoter regions of CHEK1, CHEK2, RAD50, RAD51 and TP53 in E2F1 ChIP-seq data and the binding sites of E2F1 were predicted on JASPAR datasets. The agarose gel electrophoresis displayed the enrichments of E2F1 in the promoter regions of CHEK1, CHEK2, RAD50, RAD51 and TP53 of LN229R. c The luciferase reporter assay displayed the E2F1 transcriptional activity in the promoter regions of CHEK1, CHEK2, RAD50, RAD51 and TP53 in LN229R (n = 3). d The TTP protein expression and E2F1 mRNA expression in LN229R, U87MGR and HG9R treated with MPC-NP or BIP-MPC-NP. e The inhibitory effect of TTP on wild-type or mutant-type ARE motifs within the E2F1 mRNA 3′-UTR in LN229R cells with MPC-NP or BIP-MPC-NP treatments (n = 3). The error bars in c and e represent the S.D. of three measurements. P value is determined by Student’s t-test. Significant results are presented as NS non-significant, *P < 0.05, **P < 0.01, ***P < 0.001.

false

Western blot - Anti-E2F1 antibody [KH95] (AB4070)
  • WB

CiteAb

Western blot - Anti-E2F1 antibody [KH95] (AB4070)

Western Blotting using Anti-E2F1 antibody [KH95]Anti-E2F1 antibody [KH95], ab4070. Publication image from Kanakkanthara, A. et al., 2019, Nat Commun, 31604914. Legend direct from paper.

ZC3H18 binds the BRCA1 promoter and inhibits E2F1 binding. a Schematic of the BRCA1 proximal promoter with E2FA and E2FB sites indicated. Nucleotide sequences of the DNA probes used in the electrophoretic mobility shift assays (EMSA). E2FA and E2FB mutation sites are indicated in open rectangles. b EMSA with purified recombinant SFB-ZC3H18 using BRCA1 promoter probe with wild-type sequence (E2FA/BWT) or mutations in the E2FA site (E2FδA), the E2FB site (E2FδB), or both E2F sites (E2FδA/B). A probe with randomly shuffled sequences was used as negative control. For supershift assays, an anti-S-Tag monoclonal antibody, which binds the SFB tag in SFB-ZC3H18, was used. c, d ZC3H18 and E2F4 co-occupy the endogenous BRCA1 promoter. Sequential ChiP (ChIP-Re-ChIP) assays in OVCAR-8 cells using anti-ZC3H18 antibody for primary ChIP and anti-E2F4 antibody for secondary ChIP (c) and using anti-E2F4 antibody for primary ChIP and anti-ZC3H18 antibody for secondary ChIP (d). e EMSA with purified recombinant SFB-ZC3H18 and SFB-E2F1 using BRCA1 promoter probe with mutated E2FB site (E2FδB). f EMSA with purified SFB-E2F4 and SFB-E2F1 using BRCA1 promoter probe with mutated E2FA site (E2FδA). The images of EMSA in b, e, and f are representative of three independent experiments that gave similar results. Data in c and d are means ± SEM of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired Student’s t-test

false

Western blot - Anti-E2F1 antibody [KH95] (AB4070)
  • WB

CiteAb

Western blot - Anti-E2F1 antibody [KH95] (AB4070)

Western Blotting using Anti-E2F1 antibody [KH95]Anti-E2F1 antibody [KH95], ab4070. Publication image from Kanakkanthara, A. et al., 2019, Nat Commun, 31604914. Legend direct from paper.

ZC3H18 occupies the BRCA1 promoter and regulates E2F1. a OVCAR-8, OVCAR-5, and PEA1 cells were processed for ChIP assays using anti-ZC3H18 or IgG control antibodies and primers specific for the BRCA1 promoter. b OVCAR-8 cells transiently expressing SFB-ZC3H18 were processed for ChIP assays using FLAG or IgG control antibodies. c, d ChIP assays showing increased occupancy of E2F1 on the BRCA1 promoter when ZC3H18 is depleted. OVCAR-8 (c) and PEA1 (d) cells transfected with control luciferase (Luc) or ZC3H18 siRNAs (siZC3) were processed for ChIP using anti-E2F1 or IgG control antibodies 48 h after transfection. e E2F1 depletion does not affect BRCA1 levels. OVCAR-8 cells were transfected with control luciferase (Luc) or two independent E2F1 siRNAs and analyzed for BRCA1, E2F1, and HSP90 levels by immunoblotting 48 h later. f DNMT1 occupancy on the BRCA1 promoter requires E2F1. OVCAR-8 cells transfected with Luc, E2F1, or ZC3H18 siRNA with our without E2F1 siRNAs were processed for ChIP with DNMT1 or control IgG antibodies 48 h after transfection. g Depletion of E2F1 restores BRCA1 expression when ZC3H18 is depleted. OVCAR-8 cells transfected with Luc, E2F1, or ZC3H18 siRNAs with our without E2F1 siRNAs were analyzed for BRCA1 mRNA levels by qRT-PCR. BRCA1 mRNA levels were normalized to GAPDH mRNA levels. Data in a–g are means ± SEM from three independent experiments. **p < 0.01, ***p < 0.001, unpaired Student’s t-test. Representative immunoblots in e are provided from three independent experiments. Unprocessed blots are provided in Source data file

false

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

KH95

Isotype

IgG2a

Carrier free

No

Reacts with

Human

Applications

IHC-P, WB

applications

Immunogen

Recombinant Full Length Protein corresponding to Human E2F1.

Q01094

Specificity

Protein of 60 kDa.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/25 - 1/50", "IHCP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purity
IgG fraction
Storage buffer
pH: 7.3 - 7.5 Preservative: 0.05% Sodium azide Constituents: Ascites, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The E2F1 protein also known as E2F transcription factor 1 is an important regulator of the cell cycle. It has a molecular weight of approximately 47 kDa. E2F1 protein is expressed in many tissues with higher expression levels in proliferating cells. It often acts as a transcription factor by binding to specific DNA sequences controlling the transition of cells from G1 to S phase of the cell cycle. This role is vital for the proper progression of the cycle and cellular proliferation.
Biological function summary

E2F1 plays a significant role in cell growth regulation and apoptosis. E2F1 functions within a complex often forming heterodimers with DP proteins. This combination enhances its ability to bind DNA and activate transcription of genes necessary for DNA replication and cell cycle progression. E2F1 also participates in the control of apoptosis by regulating the expression of pro-apoptotic genes balancing cell proliferation and death.

Pathways

E2F1 is deeply embedded in cell cycle regulatory pathways and the p53 signaling pathway. It closely interacts with proteins like RB (Retinoblastoma protein) and p53. RB protein regulates E2F1 activity by controlling its release while p53 helps in mediating the cell's response to DNA damage potentially leading to either cell cycle arrest or apoptosis. These interactions highlight E2F1's role in maintaining cellular homeostasis.

E2F1 is often linked to cancer and neurodegenerative diseases. Overexpression or dysregulation of E2F1 can lead to uncontrolled cell proliferation contributing to oncogenesis. In the context of neurodegenerative diseases E2F1 influences neuronal apoptosis and may be associated with disorders such as Alzheimer's. E2F1 interacts with other proteins such as p53 in cancer where it affects both cell cycle dynamics and apoptosis illustrating its complex involvement in disease progression.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication (PubMed : 10675335, PubMed : 12717439, PubMed : 17050006, PubMed : 17704056, PubMed : 18625225, PubMed : 28992046). The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase (PubMed : 10675335, PubMed : 12717439, PubMed : 17704056). E2F1 binds preferentially RB1 in a cell-cycle dependent manner (PubMed : 10675335, PubMed : 12717439, PubMed : 17704056). It can mediate both cell proliferation and TP53/p53-dependent apoptosis (PubMed : 8170954). Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters (PubMed : 20176812). Directly activates transcription of PEG10 (PubMed : 17050006, PubMed : 18625225, PubMed : 28992046). Positively regulates transcription of RRP1B (PubMed : 20040599).
See full target information E2F1

Publications (21)

Recent publications for all applications. Explore the full list and refine your search

iScience 27:110462 PubMed39104405

2024

SHP2 mutations promote glycolysis and inhibit apoptosis via PKM2/hnRNPK signaling in colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Bo Zhou,Zhuoyang Fan,Guodong He,Wei Zhang,Guowei Yang,Lechi Ye,Jianmin Xu,Rong Liu

Cancer gene therapy 30:1007-1017 PubMed36973424

2023

E2F1-mediated KDM4A-AS1 up-regulation promotes EMT of hepatocellular carcinoma cells by recruiting ILF3 to stabilize AURKA mRNA.

Applications

Unspecified application

Species

Unspecified reactive species

Hao-Ming Shen,Di Zhang,Ping Xiao,Bin Qu,Yi-Fan Sun

Toxicology research 11:831-840 PubMed36337239

2022

Resveratrol alleviates Ang II-induced vascular smooth muscle cell senescence by upregulating E2F1/SOD2 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Lei Liu,Xiuhua Yang,Yiyang Liao,Chuanhua Wang,Yuanliang Wang

Disease markers 2022:6329097 PubMed36016851

2022

circCNN2 Accelerates Cell Proliferation and Invasion in Lung Squamous Cell Carcinoma via Regulating miR-184/E2F1 and Activating MAPK Signaling Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Shan Hu,Peng Cao,Kangle Kong,Peng Han,Jiaqi Yue,Yu Deng,Fan Li,Bo Zhao

Translational oncology 18:101304 PubMed35144091

2022

LncRNA DLGAP1-AS2 promotes the radioresistance of rectal cancer stem cells by upregulating CD151 expression via E2F1.

Applications

Unspecified application

Species

Unspecified reactive species

Sheng-Ying Xiao,Zhi-Guang Yan,Xiao-Dong Zhu,Jun Qiu,Yi-Chen Lu,Fu-Ren Zeng

Disease markers 2021:6256369 PubMed34616498

2021

E2F1-Induced lncRNA BAIAP2-AS1 Overexpression Contributes to the Malignant Progression of Hepatocellular Carcinoma via miR-361-3p/SOX4 Axis.

Applications

Unspecified application

Species

Unspecified reactive species

Yan Yang,Hong Ge,De-Qing Li,Ai-Xia Xu

Nucleic acids research 49:10419-10430 PubMed34520549

2021

The fate of notch-1 transcript is linked to cell cycle dynamics by activity of a natural antisense transcript.

Applications

Unspecified application

Species

Unspecified reactive species

Filip Vujovic,Saba Rezaei-Lotfi,Neil Hunter,Ramin M Farahani

Oncology letters 22:531 PubMed34079590

2021

MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression.

Applications

Unspecified application

Species

Unspecified reactive species

Cun Gao,Rui Dong,Yongmeng Li,Jinghui Liang,Hui Tian

Journal of experimental & clinical cancer research 39:216 PubMed33054826

2020

Long noncoding RNA Linc00337 functions as an E2F1 co-activator and promotes cell proliferation in pancreatic ductal adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Huakai Wang,Shiyong Yu,Huan Peng,Yijun Shu,Wenjie Zhang,Qi Zhu,Yingxia Wu,Yijun Xu,Jiqi Yan,Honggang Xiang

Nature communications 11:594 PubMed32001707

2020

Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.

Applications

Unspecified application

Species

Unspecified reactive species

Xiangqi Meng,Yu Zhao,Bo Han,Caijun Zha,Yangong Zhang,Ziwei Li,Pengfei Wu,Tengfei Qi,Chuanlu Jiang,Yang Liu,Jinquan Cai
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com